Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company specializing in the development of bioengineered human tissues, has announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a price of $1.05 per share. The offering is expected to raise gross proceeds of approximately $50 million, with the closing anticipated on or about June 12, 2026, pending customary closing conditions. Additionally, the underwriters have been granted a 30-day option to purchase up to 7,142,857 additional shares at the public offering price, which could further enhance the total capital raised.

Founded in 2004 and headquartered in Durham, North Carolina, Humacyte is pioneering the development of universally implantable, bioengineered human tissues at commercial scale. The company’s flagship product, Symvess®, received FDA approval and was commercially launched in the United States in early 2025. Humacyte’s innovative approach focuses on creating off-the-shelf, acellular human tissues designed to treat a variety of medical conditions, particularly in vascular applications. The proceeds from the current offering will primarily fund the commercialization of Symvess®, support the planned filing of a Biologics License Application supplement for a hemodialysis indication, and advance the development of additional product candidates in its pipeline.

The biotechnology sector has seen significant activity in recent years, with companies like Humacyte at the forefront of developing novel therapies and technologies aimed at addressing unmet medical needs. The ability to manufacture bioengineered tissues at scale represents a transformative shift in treatment options for patients, particularly those suffering from chronic conditions requiring surgical intervention. As healthcare systems increasingly prioritize innovative solutions to improve patient outcomes, companies that can demonstrate both efficacy and safety in their products are likely to attract investor interest.

The successful pricing of this public offering underscores investor confidence in Humacyte’s strategic direction and its potential to deliver on its growth objectives. With the funds raised, Humacyte aims to enhance its operational capabilities and accelerate the commercialization of its products, positioning itself as a key player in the biotechnology landscape. As the company continues to advance its development programs, it may also set the stage for further collaborations or partnerships that could amplify its market presence.

Overall, the current offering reflects broader trends in the biotechnology market, where access to capital remains crucial for innovation and growth. As more companies pursue public offerings to fund their research and development efforts, the sector is likely to experience continued investment interest, particularly in areas that promise to revolutionize patient care. The implications of this offering extend beyond Humacyte, potentially influencing investor sentiment and funding dynamics across the biotechnology industry.